{"DataElement":{"publicId":"2464443","version":"1","preferredName":"Prostate Carcinoma Hormone Therapy Refractory Assessment Type","preferredDefinition":"the type of assessment or method to determine whether a prostate cancer was unresponsive to hormone therapy.","longName":"PROS_HOR_REF_ASS_TP","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2464440","version":"1","preferredName":"Prostate Carcinoma Hormone Therapy Refractory Assessment","preferredDefinition":"information related to the assessment method of prostate carcinoma, a carcinoma arising in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland, that fails to respond to various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level.","longName":"PRSCA_HORM_REF_ASS","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2744055","version":"1","preferredName":"Prostate Carcinoma","preferredDefinition":"Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002","longName":"C4863","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B8AEEC8-FDF2-03F8-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-04-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-04-23","modifiedBy":"ONEDATA","dateModified":"2008-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2744056","version":"1","preferredName":"Hormone Therapy Refractory Assessment","preferredDefinition":"Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level. The treatment may include administration of hormones or hormone analogs to the patient, or decreasing the level of hormones in the body by using hormone antagonists, or hormone ablation therapy. The concept covers but not limited to: intermittent or permanent hormone suppression or ablation in treatment of hormone-dependent tumors, hormone replacement therapy of any kind, hormonal component of gender reassignment therapy, hormonal contraception, surgical and radiation castration.:Refractory; not responding to treatment.:The final result of a determination of the value, significance, or extent of.","longName":"C15445:C38014:C25367","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hormone Therapy","conceptCode":"C15445","definition":"Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Refractory","conceptCode":"C38014","definition":"Not responding to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Assessment","conceptCode":"C25367","definition":"The final result of a determination of the value, significance, or extent of.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B8AEEC8-FE04-03F8-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-04-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-04-23","modifiedBy":"ONEDATA","dateModified":"2008-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F836E72-1F82-3EB2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-22","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-03-22","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2464441","version":"1","preferredName":"Unresponsive Prostate Carcinoma Type","preferredDefinition":"the type of unresponsive prostate cancer.","longName":"UNRESP_PROST_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"75","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Progression of non-measurable disease","valueDescription":"Progression of non-measurable disease","ValueMeaning":{"publicId":"2578385","version":"1","preferredName":"Progression of non-measurable disease","longName":"2578385","preferredDefinition":"Progression of non-measurable disease","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FF3E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-22","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-03-22","modifiedBy":"CAMPBELB","dateModified":"2006-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F978AB9-8648-600A-E044-0003BA3F9857","beginDate":"2006-03-22","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-03-22","modifiedBy":"ONEDATA","dateModified":"2006-03-22","deletedIndicator":"No"},{"value":"Progression of measurable disease","valueDescription":"Progression of measurable disease","ValueMeaning":{"publicId":"2578384","version":"1","preferredName":"Progression of measurable disease","longName":"2578384","preferredDefinition":"Progression of measurable disease","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FF3D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-22","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-03-22","modifiedBy":"CAMPBELB","dateModified":"2006-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F978AB9-8644-600A-E044-0003BA3F9857","beginDate":"2006-03-22","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-03-22","modifiedBy":"ONEDATA","dateModified":"2006-03-22","deletedIndicator":"No"},{"value":"Rising PSA","valueDescription":"Rising PSA","ValueMeaning":{"publicId":"2578386","version":"1","preferredName":"Rising PSA","longName":"2578386","preferredDefinition":"Rising PSA","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FF3F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-22","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-03-22","modifiedBy":"CAMPBELB","dateModified":"2006-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F978AB9-864C-600A-E044-0003BA3F9857","beginDate":"2006-03-22","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-03-22","modifiedBy":"ONEDATA","dateModified":"2006-03-22","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F836E72-1F94-3EB2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-22","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-03-22","modifiedBy":"SBR","dateModified":"2008-12-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811910","version":"1","longName":"Prostate","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811963","version":"1","longName":"Treatment","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"CRF Text","type":"Preferred Question Text","description":"Disease deemed unresponsive to hormone therapy by","url":null,"context":"CTEP"}],"origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"0F997EC3-954B-644C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-22","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-03-22","modifiedBy":"CAMPBELB","dateModified":"2008-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}